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Abstract
Importance—Our understanding of risk factors for childhood stroke is incomplete. In adults, 
migraine with aura is associated with a two-fold increase in ischemic stroke risk.
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Objective—In this cohort study we examine the association between migraine and stroke among 
children in Kaiser Permanente Northern California (KPNC).
Design, Setting, and Participants—Children ages 2-17 years who were members of KPNC 
for ≥6 months between1997-2007 were included. Migraine cohort members had one or more of: 
an ICD-9 code for migraine, migraine listed as a significant health problem, or a prescription for a 
migraine-specific medication. The comparison group was children with no evidence of headache.
Main outcome measures—stroke incidence rates and incidence rate ratios (IR).
Results—Among the 1,566,952 children within KPNC during the study period, 88,164 had 
migraine, and 1,323,142 had no evidence of headache. Eight migraineurs had a stroke (3 [38%] 
hemorrhagic; 5 [63%]ischemic). Eighty strokes occurred in children without headache, (53 
[66%]hemorrhagic;27 [34%] ischemic). The ischemic stroke incidence rate was 0.9/100,000 
person-years in migraineurs vs. 0.4/100,000 person-years in those without headache; IR 2.0 (95% 
CI 0.8-5.2). A post-hoc analysis of adolescents (12-17 years) showed an increased risk of ischemic 
stroke among those with migraine; IR 3.4(95% CI 1.2-9.5). The hemorrhagic stroke incidence rate 
was 0.5/100,000 person-years in migraineurs and 0.9/100,000 person-years in those without 
headache; IR 0.6 (95% CI 0.2-2.0).
Conclusions—There was no statistically significant increase in hemorrhagic or ischemic stroke 
risk in pediatric migraineurs in this cohort study. A post-hoc analysis found that ischemic stroke 
risk was significantly elevated in adolescents with migraine. Future studies should focus on 
identifying risk factors for ischemic stroke among adolescent migraineurs. Based on adult data, we 
recommend that migraine aura status should be studied as a possible risk factor for ischemic stroke 
among adolescent migraineurs.
Keywords
migraine; childhood stroke; pediatric stroke; aura
Introduction
Childhood stroke is more common than previously thought, with an ischemic stroke 
incidence rate of 1.3 per 100,000 person-years at risk(1). Although children with congenital 
heart disease, sickle cell disease, prothrombotic conditions, and autoimmune diseases have 
an increased risk of ischemic stroke, most children with stroke are previously healthy(2-5). 
Recent studies (3, 6)suggests that minor infections and head or neck trauma are prevalent 
risk factors for childhood stroke; however, these are common disorders in childhood, 
whereas stroke is rare, suggesting that stroke in children is multifactorial. A better 
understanding of stroke risk factors is needed to guide primary and secondary stroke 
prevention strategies in children.
In adults, migraine with aura is associated with an approximately two-fold increased risk of 
ischemic stroke(7). Recent studies have also suggested an increased risk of hemorrhagic 
stroke in adults with migraine(8-10). Migraine is a common neurologic disorder 
characterized by episodes of headache accompanied by sensitivity symptoms such as 
photophobia, phonophobia, nausea and vomiting(11). Migraine is common among children 
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and the prevalence increases with age throughout adolescence; by age ten the one-year 
prevalence in the U.S. is approximately 5%(12). If migraine is as strongly associated with 
stroke in children as it is in adults, it would be the most common chronic condition 
associated with stroke in this age group.
This retrospective cohort study examines whether migraine is associated with an increased 
risk of ischemic or hemorrhagic stroke in a population of children enrolled in a large 
managed care organization, Kaiser Permanente Northern California (KPNC). Given that 
migraine has been associated with both ischemic and hemorrhagic stroke in adults, and that 
nearly half of all strokes in children are hemorrhagic(13), we examined for an association 
with each stroke type and for an association with the two types combined.
Methods
Ethical approvals—The study protocol was approved by the Committees for Human 
Research at University of California, San Francisco and KPNC. Procedures followed were 
in accordance with institutional guidelines.
Study setting—KPNC is a large integrated healthcare delivery system that provides care 
to approximately 30% of the population of northern California. The members of KPNC are 
demographically similar to the overall population of California, except that the very wealthy 
and very poor are underrepresented(14). KPNC maintains extensive electronic databases that 
include demographics, all inpatient and outpatient diagnoses, pharmacy records, and 
radiology records.
Study population—The study cohort consisted of KPNC members ages 2-17 years with 
at least one continuous membership period of ≥6 months during the study period 
(1997-2007). Pediatric stroke is most common in the neonatal period, followed by the period 
from age 29 days to two years(1), however diagnosis of migraine typically is not given to 
children in this age range. Therefore children younger than age 2 years were excluded. 
Those children who had a gap in membership during the study period were allowed to re-
enter the cohort and contribute more person time to the analysis as long as they returned for 
a minimum of 6 contiguous months while they were still age <18 years.
Determination of stroke outcomes—Stroke outcomes were ascertained previously as 
part of the Kaiser Pediatric Stroke Study (KPSS) and the methods for stroke determination 
have been described previously(1). The methods to identify pediatric stroke cases in KPSS 
were more comprehensive than in previous pediatric stroke research, and accuracy was 
assured via independent case confirmation by a child neurologist board-certified in vascular 
neurology (HJF). In brief, KPSS used two search strategies to identify potential cases of 
pediatric ischemic stroke: (1) diagnostic (ICD-9) code searches for inpatient and outpatient 
diagnoses suggestive of hemorrhagic or ischemic stroke; and (2) radiology text string 
searches of all pediatric head imaging reports for terms suggestive of ischemic stroke. The 
full imaging reports were then reviewed by a pediatric stroke expert (HJF) to exclude those 
not consistent with stroke. For hemorrhagic stroke, cases were ascertained through ICD-9 
search as it was not feasible to review all imaging reports given the large number that 
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comment on presence or absence of blood. Traumatic hemorrhagic stroke cases were 
included given that changes in concentration or vision during a migraine attack could put a 
child at higher risk for a traumatic hemorrhagic stroke. All stroke cases were confirmed 
through chart review by two independent neurologists using predefined clinical and 
radiographic criteria; disagreements were resolved through adjudication by a third 
neurologist.
Determination of migraine status
To be included in the migraine group, a child had to have one or more of the following: 1) 
an ICD-9 code for migraine (i.e., any 346.XX code) from any encounter, 2) migraine listed 
on their significant health problem list, or 3) pharmacy records showing a prescription of a 
migraine-specific medication. The migraine-specific medications included in the search 
were: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, 
dihydroergotamine, and ergotamine. Almotriptan and rizatriptan are now approved by the 
Federal Drug Administration for use in children (almotriptan for ages 12-17, rizatriptan for 
ages 6-17 years); the remainder of the listed medications have been studied for migraine in 
pediatrics and/or are used clinically off label(15-31). To qualify via pharmacy records there 
also had to be no ICD-9 code for cluster headache, as this is the only other diagnosis these 
medications could be used to treat.
Previous research within KPNC has shown that the coding error rate for migraine ICD-9 
codes is very low, however the sub-type of migraine (i.e., with or without aura) is not 
accurate(32), therefore it is not possible to reliably subdivide those migraineurs with aura 
from those without based on ICD-9 code.
Because there is a high potential for ascertainment bias following a stroke diagnosis, as all 
children with stroke are evaluated by a neurologist, it was required that a child be seen 
clinically for headache prior to the stroke date in order to be included in the migraine group. 
Charts were also reviewed for those children, whose medical encounter for headache 
occurred prior to their stroke date, and who ultimately went on to be diagnosed with 
migraine. This was to ensure there was no identifiable cause of the headaches (other than 
migraine) prior to the stroke date; specifically, head trauma and infection were ruled out. 
Previous research indicates that 94% of adult patients who come to the primary care doctor 
for recurrent headaches have migraine or probable migraine(33), therefore it was assumed 
that these children who had headache severe enough to report to a doctor, who ultimately 
received a diagnosis of migraine were experiencing migraine attacks prior to their stroke 
date—they simply had a delay in diagnosis.
Comparison group
It is estimated that only 48% of adult migraineurs in the U.S. have ever been diagnosed by a 
physician(34), and the likelihood that the rate of under-diagnosis is even higher in 
children(35). Therefore, the primary comparison group consisted of children with no 
evidence of headache in order to minimize contamination by undiagnosed migraineurs. To 
be included in the no-headache comparison group, children had to have no evidence of any 
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ICD-9 code for headache of any type, and could not have headache listed as a significant 
health problem.
Statistical analysis
Pediatric ischemic and hemorrhagic stroke incidence rates per 100,000 person-years were 
calculated for the migraine group and the no-headache comparison group. Incidence rate 
ratios (IR) and 95% confidence intervals were then calculated as a measure of relative risk.
The primary analysis was the ischemic stroke incidence rate ratio between the migraine 
group and the no-headache comparison as the association between migraine and ischemic 
stroke is most clearly elucidated in adults. Secondary analyses included: 1) stroke (overall) 
incidence rate ratio between the migraine group and the no-headache group, and 2) the 
hemorrhagic stroke incidence rate ratio between the migraine group and the no-headache 
group. When our primary analysis demonstrated that children in the migraine group who had 
ischemic strokes were older than those in the no-headache comparison group, we performed 
a post-hoc stratified analysis considering ischemic stroke incidence rates and rate ratios 
among those 12-17 years old (with person-time only contributed between ages12-17). 
Statistical analyses were performed using SAS 9.3 (Cary, North Carolina)and Stata v. 12.0 
(College Station, Texas). A p-value of <0.05 was considered significant, and two-sided tests 
were used.
Results
There were 1,566,952 children in the study cohort. Of these, 88,164(6%) had migraine. 
Another 155,646 had some evidence of headache in their chart, and so were removed from 
the analysis given the possibility they might have undiagnosed migraine. The other 
1,323,142 had no evidence of headache and constituted the no-headache comparison group. 
The patient characteristics of the cohort are shown in Table 1. The mean age of the migraine 
group was older (9.2 years (SD 4.6) compared to 7.5 years (SD 4.9), p<0.0001).
The children experienced 88 strokes during the study period (32 ischemic, and 56 
hemorrhagic). The characteristics of the children who had strokes are shown in Table 2. 
Children who had ischemic stroke in the migraine group were older than those who had 
ischemic stroke in the no-headache group.
Stroke location, etiology, hospital course details, and stroke outcome data are also shown in 
Table 2. There were no statistically significant differences between groups in terms of 
proportion requiring ICU admission, hospital length of stay, proportion with a persistent 
neurologic deficit, or mortality.
The number of children who suffered a stroke in each group is shown in Table 3, along with 
the number who had hemorrhagic and ischemic strokes in each group and stroke incidence 
rates and rate ratios. While the rate of ischemic stroke was higher in the migraine group 
compared with the no-headache group, the 95% confidence interval for the incidence rate 
ratio overlapped the null (IR 2.0, 95% CI 0.8-5.2). However, when this analysis was 
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restricted to 12-17 year olds, the ischemic stroke incidence rate was higher in the migraine 
group (IR 3.4 (1.2-9.5)).
Discussion
Results of our large retrospective study of KPNC children show that there is no statistically 
significant elevation in combined ischemic and hemorrhagic stroke risk among children with 
migraine. Migraine was also not associated with increased risk of hemorrhagic stroke in this 
study.
The incidence rate ratio for the risk of ischemic stroke among children with migraine 
compared to a comparison group of children without headache was 2.0 (95% CI 0.8-5.2). 
Given the small number of ischemic strokes in the study, the confidence interval was too 
wide to exclude the possibility of no effect.
However, a post-hoc analysis showed that the ischemic stroke incidence rate ratio was 
elevated in adolescents (ages 12-17 years) with migraine compared to those without 
headache (IR 3.4 (1.2-9.5)). Of note, all five of the ischemic strokes in the migraine group 
occurred in adolescents. While this was a post-hoc analysis, it leads us to hypothesize that an 
elevated risk of ischemic stroke exists in adolescents with migraine but not in pre-pubertal 
children with migraine. This suggests there may be a hormonal effect mediating the 
relationship between adolescent migraine and stroke risk, and in fact evidence of such a 
hormonal effect is seen in adult migraineurs wherein reproductive age women with migraine 
with aura have an increased risk for ischemic stroke. In adults, migraine with aura is 
associated with an approximately two-fold increased risk of ischemic stroke, with results 
from two meta-analyses reporting odds ratios of 2.51 (95% CI 1.52-4.14)(36) and 2.16 (95% 
CI 1.53-3.03)(7). This risk appears to be greatest among women under age forty-five (i.e. 
young women), particularly if they smoke (OR 9.03, 95% CI 4.22-19.34) or use estrogen-
containing contraceptives (OR 7.02; 95% CI 1.51-32.68)(7). Based on Women's Health 
Study data, migraine with aura is thought to account for an additional four ischemic strokes 
per 10,000 woman-years(37). Fortunately, these women are more likely to have non-
disabling strokes(38).
Unlike in the adult population, (8-10) we found no association between pediatric migraine 
and increased risk of hemorrhagic stroke in this study population. Of note, the stroke 
incidence rates for both ischemic and hemorrhagic stroke in all groups in this study were 
lower than the 1.3/100,000 person-years childhood stroke incidence rate observed in the 
Kaiser Pediatric Stroke study. This is likely due to the fact that we excluded the twenty-nine 
day to age two years age group in this study, and that age bracket has the highest childhood 
stroke incidence rate(1).
Our study results are generalizable as the Kaiser Permanente Northern California 
membership is representative of the general population of children in California(14). While 
an even larger study population would have been optimal, our cohort of nearly 1.6 million 
children within one medical system with integrated electronic medical records, pharmacy 
records, and radiology records provided an excellent opportunity to examine this research 
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question. While this was a retrospective study, our stroke outcomes were carefully defined 
and adjudicated.
One limitation of this study was the small number of stroke events in the migraine group. As 
such we did not have power to adjust for potential confounding or mediating factors that 
could influence the association between migraine and ischemic stroke in children and 
adolescents, such as smoking or use of oral contraceptives. Furthermore as the medical 
record did not include aura status we were not able to examine how aura might mediate the 
relationship between migraine and stroke, as it appears to do in adult women. Future 
prospective studies on stroke risk in adolescent migraineurs should aim to measure migraine 
aura status in adolescent migraineurs.
Lastly, we cannot be certain that we identified all migraineurs within the overall pediatric 
cohort. Only about half of all adults with migraine ever receive a diagnosis(34), and the 
proportion of migraineurs diagnosed is probably even lower among children. Therefore it is 
possible that even after we removed children with evidence of headache that our comparison 
group may still have been contaminated with children with undiagnosed migraine.
Because childhood stroke is still a rather rare event and migraine in children and adolescents 
is common, care must be taken in counseling parents so as not to create unnecessary anxiety. 
Parents can be reassured that even if there is an association between pediatric migraine and 
ischemic stroke, the likelihood that their child with migraine will have an ischemic stroke 
remains extremely low at 0.9/100,000 person-years. Furthermore, in adults with migraine, 
their strokes tend to result in better functional outcomes(38). There is some suggestion this 
may also be the case with pediatric stroke associated with migraine, as the hospital length of 
stay for the migraineurs in this study in both the ischemic and hemorrhagic strokes were 
shorter (though not statistically significantly). In addition there is no evidence to suggest that 
increased ischemic stroke risk extends to migraineurs without aura, and only about a quarter 
of migraineurs have aura(39-41). It would however remain prudent to counsel children and 
adolescents against smoking, given its overall detrimental health effects and the increased 
stroke risk among adult migraineurs with aura who smoke. It is more complicated to decide 
whether estrogen-containing contraceptives should be considered contra-indicated in an 
adolescent girl with migraine with aura. As the data stand there is no evidence for 
admonishing the estrogenic oral contraceptives, therefore each clinical case must be 
individualized. While their use is associated with increased stroke risk in adult women with 
migraine with aura(7), pregnancy and the post-partum state are also associated with an 
increased risk of stroke(42, 43), and a history of migraine is associated with an increased 
risk of stroke in pregnancy (OR 8.5, 1.5-62.1)(44).
The status of the relationship between adolescent migraine, particularly with aura, and 
ischemic stroke needs further evaluation and will require clinicians' careful assignment of 
diagnoses, or a biomarker for aura, to support further studies.
Acknowledgments
We would like to acknowledge Mike Sorel for his programming assistance at KPNC. The authors would like to 
thank Amy Markowitz, JD, for her helpful and insightful comments on this and earlier drafts of this manuscript.
Gelfand et al. Page 7
Cephalalgia. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Sources of Funding: This study was supported in part by a private family donation to the UCSF Pediatric Brain 
Center. Support was also provided by a UCSF Center for Translational Science Institute junior investigator award, 
and Dr. Gelfand was supported by an NIH/NINDS K12 (NS01692) while this research was conducted. 
Development of the migraine cohort was funded by a grant from NIH/NINDS 1R01NS080863-01 Genetics and 
Comorbidity of Migraine (Pressman, PI).
References
1. Agrawal N, Johnston SC, Wu YW, Sidney S, Fullerton HJ. Imaging data reveal a higher pediatric 
stroke incidence than prior US estimates. Stroke; a journal of cerebral circulation. 2009; 40(2009):
3415–21.
2. Mallick AA, Ganesan V, Kirkham FJ, Fallon P, Hedderly T, McShane T, et al. Childhood arterial 
ischaemic stroke incidence, presenting features, and risk factors: a prospective population-based 
study. Lancet neurology. 2014; 13(2014):35–43. [PubMed: 24304598] 
3. Hills NK, Johnston SC, Sidney S, Zielinski BA, Fullerton HJ. Recent trauma and acute infection as 
risk factors for childhood arterial ischemic stroke. Annals of neurology. 2012; 72(2012):850–8. 
[PubMed: 23280836] 
4. Dowling MM, Hynan LS, Lo W, Licht DJ, McClure C, Yager JY, et al. International Paediatric 
Stroke Study: stroke associated with cardiac disorders. International journal of stroke : official 
journal of the International Stroke Society. 2013; 8(Suppl A100)(2013):39–44. [PubMed: 
23231361] 
5. Mackay MT, Wiznitzer M, Benedict SL, Lee KJ, Deveber GA, Ganesan V. International Pediatric 
Stroke Study G. Arterial ischemic stroke risk factors: the International Pediatric Stroke Study. 
Annals of neurology. 2011; 69(2011):130–40. [PubMed: 21280083] 
6. Hills NK, Sidney S, Fullerton HJ. Timing and number of minor infections as risk factors for 
childhood arterial ischemic stroke. Neurology. 2014; 83(2014):890–7. [PubMed: 25142897] 
7. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular 
disease: systematic review and meta-analysis. Bmj. 2009; 339(2009):b3914. [PubMed: 19861375] 
8. Kuo CY, Yen MF, Chen LS, Fann CY, Chiu YH, Chen HH, Pan SL. Increased risk of hemorrhagic 
stroke in patients with migraine: a population-based cohort study. PloS one. 2013; 8(2013):e55253. 
[PubMed: 23372843] 
9. Kurth T, Kase CS, Schurks M, Tzourio C, Buring JE. Migraine and risk of haemorrhagic stroke in 
women: prospective cohort study. Bmj. 2010; 341(2010):c3659. [PubMed: 20736268] 
10. Sacco S, Ornello R, Ripa P, Pistoia F, Carolei A. Migraine and hemorrhagic stroke: a meta-
analysis. Stroke; a journal of cerebral circulation. 2013; 44(2013):3032–8.
11. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24(Suppl 
1)(2004):9–160. [PubMed: 14979299] 
12. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the 
United States: a life-span study. Cephalalgia : an international journal of headache. 2010; 
30(2010):1065–72. [PubMed: 20713557] 
13. Fullerton HJ, Wu YW, Zhao S, Johnston SC. Risk of stroke in children: ethnic and gender 
disparities. Neurology. 2003; 61(2003):189–94. [PubMed: 12874397] 
14. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and 
application of a census-based methodology. American journal of public health. 1992; 82(1992):
703–10. [PubMed: 1566949] 
15. Christensen ML, Eades SK, Fuseau E, Kempsford RD, Phelps SJ, Hak LJ. Pharmacokinetics of 
naratriptan in adolescent subjects with a history of migraine. Journal of clinical pharmacology. 
2001; 41(2001):170–5. [PubMed: 11210397] 
16. Elkind AH, Wade A, Ishkanian G. Pharmacokinetics of frovatriptan in adolescent migraineurs. 
Journal of clinical pharmacology. 2004; 44(2004):1158–65. [PubMed: 15342617] 
17. Hewitt DJ, Pearlman E, Hamalainen M, Lewis D, Connor KM, Michelson D, et al. Long-term 
open-label safety study of rizatriptan acute treatment in pediatric migraineurs. Headache. 2013; 
53(2013):104–17. [PubMed: 23078588] 
18. Hamalainen ML, Hoppu K, Santavuori PR. Oral dihydroergotamine for therapy-resistant migraine 
attacks in children. Pediatric neurology. 1997; 16(1997):114–7. [PubMed: 9090684] 
Gelfand et al. Page 8
Cephalalgia. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
19. MacDonald JT. Treatment of juvenile migraine with subcutaneous sumatriptan. Headache. 1994; 
34(1994):581–2. [PubMed: 7843952] 
20. Hamalainen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a 
randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan 
differently from adults? Neurology. 1997; 48(1997):1100–3. [PubMed: 9109909] 
21. Linder SL, Mathew NT, Cady RK, Finlayson G, Ishkanian G, Lewis DW. Efficacy and tolerability 
of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache. 
2008; 48(2008):1326–36. [PubMed: 18484981] 
22. Lewis DW, Winner P, Hershey AD, Wasiewski WW. Adolescent Migraine Steering C. Efficacy of 
zolmitriptan nasal spray in adolescent migraine. Pediatrics. 2007; 120(2007):390–6. [PubMed: 
17671066] 
23. Winner P, Rothner AD, Saper J, Nett R, Asgharnejad M, Laurenza A, et al. A randomized, double-
blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in 
adolescents. Pediatrics. 2000; 106(2000):989–97. [PubMed: 11061765] 
24. Ahonen K, Hamalainen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of 
migraine attacks in children: A randomized trial. Neurology. 2004; 62(2004):883–7. [PubMed: 
15037686] 
25. Ahonen K, Hamalainen ML, Eerola M, Hoppu K. A randomized trial of rizatriptan in migraine 
attacks in children. Neurology. 2006; 67(2006):1135–40. [PubMed: 16943370] 
26. Ueberall MA, Wenzel D. Intranasal sumatriptan for the acute treatment of migraine in children. 
Neurology. 1999; 52(1999):1507–10. [PubMed: 10227648] 
27. Rothner AD, Winner P, Nett R, Asgharnejad M, Laurenza A, Austin R, Peykamian M. One-year 
tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a 
multicenter, open-label study. Clinical therapeutics. 2000; 22(2000):1533–46. [PubMed: 
11192144] 
28. Evers S, Rahmann A, Kraemer C, Kurlemann G, Debus O, Husstedt IW, Frese A. Treatment of 
childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology. 2006; 67(2006):497–
9. [PubMed: 16775229] 
29. Ho TW, Pearlman E, Lewis D, Hamalainen M, Connor K, Michelson D, et al. Efficacy and 
tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, 
placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia : an international 
journal of headache. 2012; 32(2012):750–65. [PubMed: 22711898] 
30. Kabbouche MA, Powers SW, Segers A, LeCates S, Manning P, Biederman S, et al. Inpatient 
treatment of status migraine with dihydroergotamine in children and adolescents. Headache. 2009; 
49(2009):106–9. [PubMed: 19125879] 
31. Gelfand AA, Goadsby PJ. Treatment of pediatric migraine in the emergency room. Pediatric 
neurology. 2012; 47(2012):233–41. [PubMed: 22964436] 
32. Pressman, A.; Jacobson, A.; Gelfand, AA.; Huynh, C.; Hamilton, L.; Avins, A. Prevalence of 
Migraine in a Diverse Community: Electronic Methods for Migraine Ascertainment in a Large 
Integrated Health Plan. IASP; Milan, Italy: 2012. 
33. Tepper SJ, Dahlof CG, Dowson A, Newman L, Mansbach H, Jones M, et al. Prevalence and 
diagnosis of migraine in patients consulting their physician with a complaint of headache: data 
from the Landmark Study. Headache. 2004; 44(2004):856–64. [PubMed: 15447694] 
34. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: 
results from the American Migraine Study II. Headache. 2001; 41(2001):638–45. [PubMed: 
11554951] 
35. Aromaa M, Sillanpaa ML, Rautava P, Helenius H. Childhood headache at school entry: a 
controlled clinical study. Neurology. 1998; 50(1998):1729–36. [PubMed: 9633718] 
36. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and 
ischemic stroke risk: an updated meta-analysis. The American journal of medicine. 2010; 
123(2010):612–24. [PubMed: 20493462] 
37. Kurth T, Diener HC. Migraine and stroke: perspectives for stroke physicians. Stroke; a journal of 
cerebral circulation. 2012; 43(2012):3421–6.
Gelfand et al. Page 9
Cephalalgia. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
38. Rist PM, Buring JE, Kase CS, Schurks M, Kurth T. Migraine and functional outcome from 
ischemic cerebral events in women. Circulation. 2010; 122(2010):2551–7. [PubMed: 21126968] 
39. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. 
Cephalalgia : an international journal of headache. 1992; 12(1992):221–8. discussion 186. 
[PubMed: 1525797] 
40. Russell MB, Rasmussen BK, Fenger K, Olesen J. Migraine without aura and migraine with aura 
are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs 
from the general population. Cephalalgia : an international journal of headache. 1996; 16(1996):
239–45. [PubMed: 8792035] 
41. Merikangas KR. Contributions of epidemiology to our understanding of migraine. Headache. 2013; 
53(2013):230–46. [PubMed: 23432441] 
42. Kittner SJ, Stern BJ, Feeser BR, Hebel R, Nagey DA, Buchholz DW, et al. Pregnancy and the risk 
of stroke. The New England journal of medicine. 1996; 335(1996):768–74. [PubMed: 8703181] 
43. Kuczynski A, Crawford S, Bodell L, Dewey D, Barlow KM. Characteristics of post-traumatic 
headaches in children following mild traumatic brain injury and their response to treatment: a 
prospective cohort. Developmental medicine and child neurology. 2013; 55(2013):636–41. 
[PubMed: 23560811] 
44. Scott CA, Bewley S, Rudd A, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. Incidence, risk 
factors, management, and outcomes of stroke in pregnancy. Obstetrics and gynecology. 2012; 
120(2012):318–24. [PubMed: 22825091] 
Abbreviations
ICHD International classification of Headache Disorders
KPNC Kaiser Permanente Northern California
IR incidence rate ratio
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Bullet Points
• There does not appear to be an increased risk of hemorrhagic stroke among 
children or adolescents with migraine
• There may be an increased risk of ischemic stroke among adolescents with 
migraine, though further study is needed as this was a post-hoc analysis.
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Table 1
Patient Characteristics of Migraine vs. No Headache Groups
Migraine (n=88,164) No Headache (n=1,323,142)
Age at entry (mean(SD)), in years* 9.2(4.6) 7.5(4.9)
Age at midpoint of follow-up (mean(SD), range), in years* 12.4 (3.7)
2-17
9.8 (4.8)
2-17
Follow-up time (mean(SD)), in years* 6.4(3.2) 4.7(3.3)
Percent female* 66% 47%
Race (percent) White 47%
Afr-American 10%
Asian 7%
Other 7%
Unknown 29%
White 30%
Afr-American 7%
Asian 11%
Other 3%
Unknown 49%
Percent Hispanic (Percent unknown) 22% (40%) 16% (61%)
Number of ischemic strokes 5 27
Number of hemorrhagic strokes 3 53
*p<0.0001
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Table 2
Comparison of Stroke Features Between the Migraine and No Headache Groups (n=88 
total)
Migraine No Headache
Ischemic Stroke:
Number of ischemic strokes 5 27
Age at stroke occurrence (mean(SD), range), in years 16.4 (0.9)
15-17
10.4 (5.1)*
2-17
Percent female 40% 30%ns
Race 1 African American
1 Hispanic
3 Caucasian
5 African American
9 Caucasian
4 Asian
5 Hispanic
1 Native American
3 Unknown
Vascular territory infarcted: 3 MCA
1 PICA
1 Not recorded—but left parietal location
18 MCA
2 ACA
3 PCA
1 PICA
5 Other vascular territory
Required ICU admission, n(%) 3/5 (60%) 17/26 (65%)ns
Hospital length of stay, mean(SD); range, in days 8(6.1); 2-16 18.2 (24.2); 1-117ns
Persistent neurologic deficit 4/5 (80%) 22/26 (85%)ns
Stroke etiology 1 Autoimmune
1 Cardiac, (atrial myxoma)
1 Idiopathic
2 Vasculopathy
6 Idiopathic
1 Cardiac
10 Vasculopathy
3 Hypercoagulability
5 Infection
2 Other
Mortality n(%) 0/5 (%) 1/27(4%)ns
Hemorrhagic Stroke:
Number of hemorrhagic strokes 3 53
Age at stroke occurrence (mean(SD), range), in years 13.3 (3.5)
10-17
10.4 (4.7)ns
2-17
Percent female 67% 32%ns
Race 1 Asian
1 Hispanic
1 Unknown
3 African-American
17 Caucasian
12 Asian
13 Hispanic
8 Unknown
Etiology 2 Structrual (1 aneurysmal, 1 AVM)
1 traumatic
26 Structural
13 Trauma
7 Idiopathic
7 Other
Required ICU admission 2/3 (66%) 40/50 (80%)ns
Hospital length of stay, mean(SD); range, in days 6.3 (6.5); 0-13 14 (15.2); 0-49ns
Persistent neurologic deficit, n (%) 0/3, (0%) 26/51 (51%)ns
Mortality, n (%) 0/3, (0%) 5/53 (9%)ns
*p-value <0.0001
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nsnot significant
MCA=middle cerebral artery
PICA=posterior inferior cerebellar artery
ACA=anterior cerebral artery
PCA=posterior cerebral artery
ICU=intensive care unit
AVM=ateriovenous malformation
SD=standard deviation
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Table 3
Stroke incidence rates and incidence rate ratios in children (2-17 years of age) enrolled in Kaiser Permanente 
Northern California (1997-2007), stratified by presence or absence of migraine.
Migraine vs. No Headache
All stroke:
Number of strokes in migraine group vs. comparison group 8 vs. 80
Incidence rate/100,000 person-years 1.4 vs. 1.3
Incidence rate ratio (95% CI) 1.1(0.5-2.3)
ISCHEMIC STROKE:
Number of strokes in migraine group vs. comparison group Overall Cohort 5 vs. 27
Ages 12-17 only 5 vs. 12
Incidence rate/100,000 person-years Overall Cohort 0.9 vs. 0.4
Ages 12-17 only 1.7 vs. 0.5
Incidence rate ratio (95% CI) Overall Cohort 2.0(0.8-5.2)
Ages 12-17 only 3.4(1.2-9.5)
HEMORRHAGIC STROKE:
Number of strokes in migraine group vs. comparison group 3 vs. 53
Incidence rate/100,000 person-years 0.5 vs. 0.9
Incidence rate ratio (95% CI) 0.6 (0.2-2.0)
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